Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, Esperion Therapeutics is itself being acquired and taken private by ...
Esperion Therapeutics ESPR shares are up during Friday’s premarket session as the company has announced a definitive agreement to be acquired by ARCHIMED. The deal will provide Esperion shareholders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results